Injectable PrEP for HIV prevention in men who have sex with men
Part of Infections clinical trials.
This trial tests a long-acting injectable HIV prevention medication (cabotegravir) as an alternative to daily pills. It may be a good fit if you are a man who has sex with men and have been taking oral PrEP consistently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a cisgender man who has sex with men.
- You are 18 years or older.
- You have been taking oral PrEP (Truvada or generic) for the past 6 months, either daily or as needed.
- You are available for follow-up in the Ile de France region (Paris area) and do not plan to travel abroad for more than 2 months.
- You are in good general health with no significant liver, kidney, or bleeding problems.
- You are not currently HIV-positive and have no symptoms of recent HIV infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to take HIV prevention medicine (PrEP) only around the time you have sex, using a pill called TAF/FTC. It aims to see if this 'on-demand' method is effective, safe, and acceptable, and could offer a more flexible option than taking a pill every day.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
This study tests a long-acting injectable medication called cabotegravir to prevent HIV in people who inject drugs. If you have injected street drugs recently, you may be able to get this shot every few months instead of taking daily pills.
This study offers three ways to prevent HIV: a shot every two months (injectable PrEP), daily pills, or a vaginal ring. Researchers in Cape Town will help you choose the option that fits your life best.
This study tests an all-in-one HIV prevention package for young men at higher risk of HIV. It combines a new long-acting PrEP (injectable HIV prevention) with mobile health support and sexually transmitted infection prevention. The goal is to see if this comprehensive approach works better than standard care.
Hear when a new Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.